We are investigating whether the combination of Mosunetuzumab and Lenalidomide is more effective than standard treatments for patients with relapsed or refractory Marginal Zone Lymphoma. The study aims to assess how well this new treatment works and its safety.
Health conditions and diseases that the clinical trial is designed to study and treat.
Marginal Zone Lymphoma (MZL) is a type of non-Hodgkin lymphoma that originates in the marginal zone of lymphoid tissue. When it is refractory, it means that the lymphoma has not responded to standard treatments, making management more complex.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
